1	<b>RetroTest unravels LINE-1 retrotransposition in</b>
2	Head and Neck Squamous Cell Carcinoma
3	
4	Jenifer Brea-Iglesias <sup>1,2#</sup> , Ana Oitabén <sup>1,2#</sup> , Sonia Zumalave <sup>2</sup> , Bernardo Rodriguez-
5	Martin <sup>2,3</sup> , María Gallardo-Gómez <sup>1</sup> , Martín Santamarina <sup>2</sup> , Ana Pequeño-Valtierra <sup>2</sup> ,
6	Laura Juaneda-Magdalena <sup>1</sup> , Ramón García-Escudero <sup>4</sup> , José Luis López-Cedrún <sup>5</sup> ,
7	Máximo Fraga <sup>6</sup> , José MC Tubio <sup>2</sup> , Mónica Martínez-Fernández <sup>*1,2</sup>
8	#Equal contribution
9	
10	1. Translational Oncology Research Group; Galicia Sur Health Research Institute
11	(IIS Galicia Sur). SERGAS-UVIGO. Estrada de Clara Campoamor, 341, 36213 Vigo,
12	(Spain).
13	2. Mobile Genomes Lab. Centre for Research in Molecular Medicine and Chronic
14	Diseases (CiMUS). (Universidad de Santiago de Compostela). Avda. Barcelona 31,
15	15706 Santiago de Compostela (Spain).
16	3. Present address: Centre for Genomic Regulation (CRG), The Barcelona Institute
17	of Science and Technology, Barcelona (Spain). Universitat Pompeu Fabra (UPF),
18	Barcelona (Spain).
19	4. Molecular and Translational Oncology Division, CIEMAT (ed 70A), Ave
20	Complutense 40, 28040 Madrid (Spain). Research Institute Hospital 12 de Octubre
21	(imas12), 28041 Madrid (Spain). Centro de Investigación Biomédica en Red de
22	Cáncer (CIBERONC), Madrid (Spain).
23	5. Department of Maxillofacial Surgery, University Hospital of A Coruña, As Xubias,
24	84, 15006 A Coruña (Spain).
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 25 6. Pathological Anatomy. Faculty of Medicine. University Clinical Hospital & Health
- 26 Research Institute of Santiago de Compostela (IDIS). Travesa da Choupana s/n,
- 27 15706 Santiago de Compostela (Spain).
- 28
- 29 \*Corresponding author: Monica Martínez Fernández.
  30 monica.martinez@iisgaliciasur.es Translational Oncology. Galicia Sur Health
  31 Research Institute (IIS Galicia Sur). Hospital Álvaro Cunqueiro. Estrada de Clara
  32 Campoamor, 341, 36213 Vigo, (Spain).
  33
- 34

#### 35 Highlights

36

- 37 • RetroTest represents the first method to determine LINE-1 38 retrotransposition from tumor biopsies in real clinical settings.
- 39 • RetroTest not only offers global LINE-1 retrotransposition ratios but also identifies the active LINE-1 source elements. 40
- 41 RetroTest elucidates a really early LINE-1 activation in early tumor stages 42 of Head and Neck Squamous Cell Carcinoma.
- 43 • Whole Genome Analysis and LINE-1 retrotransposition demonstrates 44 processes of field cancerization in Head and Neck Squamous Cell 45 Carcinoma.
- 46 • LINE-1 retrotransposition favors an earlier and more efficient Head and 47 Neck Squamous Cell Carcinoma diagnosis.
- 48

#### 49 Abstract

50 The relevant role of LINE-1 (L1) retrotransposition in cancer has been recurrently 51 demonstrated in recent years. However, their repetitive nature hampers their 52 identification and detection, hence remaining inaccessible for clinical practice. 53 Also, its clinical relevance for cancer patients is still limited. Here, we develop a 54 new method to quantify L1 activation, called RetroTest, based on targeted 55 sequencing and a sophisticated bioinformatic pipeline, allowing its application in 56 tumor biopsies. First, we performed the benchmarking of the method and 57 confirmed its high specificity and reliability. Then, we unravel the L1 activation in HNSCC according to a more extensive cohort including all the HNSCC tumor stages. 58 59 Our results confirm that RetroTest is remarkably efficient for L1 detection in 60 tumor biopsies, reaching a high sensitivity and specificity. In addition, L1 retrotransposition estimation reveals a surprisingly early activation in HNSCC 61 62 progression, contrary to its classical association with advanced tumor stages. This 63 early activation together with the genomic mutational profiling of normal adjacent

- 64 tissues supports field cancerization process in this tumor. These results underline
- 65 the importance of estimating L1 retrotransposition in clinical practice towards an
- 66 earlier and more efficient diagnosis in HNSCC.
- 67
- 68 Keywords
- 69 Retrotransposition, LINE-1, HNSCC, early diagnosis biomarker, field cancerization

## 70 1. Introduction

71 Approximately half of human genome is composed of transposable elements (TEs). 72 sequences with the ability of moving from one place to another, changing the 73 normal structure of the genome in the places where they are integrated [1,2]. 74 Among them, long interspersed nuclear element retrotransposons (LINE-1, L1) 75 represent 17% of the entire DNA content with approximately 500,000 copies, most 76 of them truncated or inactive [3–6]. Specifically, only a small subset of these L1s is 77 active in the human genome, although they stay transcriptionally repressed due to 78 epigenetic mechanisms that prevent the damage that their mobilization would 79 cause [7]. When this repression is lost, L1 activation can cause different diseases, 80 including cancer [8, 9].

In the framework of the International Consortium of PanCancer (PCAWG), our previous analyses shown that somatic L1 insertions represent the major restructuring source of cancer genomes, especially important for head-and-neck squamous cell carcinoma (HNSCC)[9]. Aberrant L1 retrotransposition contribute to instability within cancer genomes, promoting cancer-driving rearrangements that involve the loss of tumor-suppressor genes and/or the amplification of oncogenes, and favoring some cancer clones to survive and grow [9].

Bespite this demonstrated impact of L1 activation in cancer genomes, the repetitive nature of L1 elements and their dispersion along the genome hinder their real activation estimates in tumor samples, preventing its translation into patient diagnosis/prognosis. This repetitive nature compels that the majority of the available detection methods are based on Whole Genome Sequencing (WGS), unfeasible for most hospitals in their diary practice, or require such good quality

94 DNA input quantities that remain unaffordable for a clinical practice mainly based95 on small and degraded tissue biopsies.

96 HNSCC represents the second tumor type with highest L1 activation [9], but the 97 clinical implications of L1 retrotransposition are still to be elucidated. Head and 98 Neck Cancer is a heterogeneous group of cancers of which more than 90% are 99 diagnosed as HNSCC, arising in the stratified epithelium of the oral cavity, pharynx, 100 and larynx [10,11]. Tumor development is often triggered by chronic exposure to 101 tobacco or alcohol, while infection with high-risk human papillomaviruses (HPVs) 102 causes a substantial and rising proportion of these tumors [12]. The lack of 103 symptoms in the early stages together with the non-existent cancer biomarkers 104 lead towards most diagnoses at advanced stages, where the 5-year survival rate is 105 less than 50% [11]. Thus, there is an urgent need to find molecular biomarkers 106 that can facilitate an earlier diagnosis and increase patients' life expectancy.

107 Based on this, we aimed to unravel the impact of possible L1 activation along 108 HNSCC development in a clinical setting. First, we have developed a new efficient 109 method based on L1 transductions, RetroTest, to measure L1 activation even in 110 biopsies with low DNA inputs. Then, we have evaluated RetroTest sensitivity and 111 specificity, demonstrating its high values. Finally, we have assessed L1 112 retrotransposition along different tumor stages, unraveling for the fist time a really 113 early activation in HNSCC and field characterization, arising L1 as a promising 114 early diagnostic biomarker.

115

## 117 2. Materials and methods

#### 118 2.1. Patients and tumor samples

119 Tumor samples and medical records were analyzed in a series of 96 HNSCC 120 patients of 3 different cohorts (Complexo Hospitalario Universitario de A Coruña 121 (CHUAC), Biobanco Vasco and Fundación Pública Galega de Medicina Xenómica 122 (FPGMX)). The Ethical Committee for Clinical Research of Santiago-Lugo approved 123 the study (CEIC 2018/567). Fresh-frozen and FFPE HNSCC tissue biopsies were 124 collected, and characteristics of each tumor are specified in Table 1. The 125 histopathologic status was confirmed by each corresponding Pathology 126 Department following the latest TNM guidelines.

127

128 2.2. DNA isolation

Genomic DNA (gDNA) was extracted from fresh-frozen tissue and formalin-fixed paraffin-embedded (FFPE) samples using AllPrep DNA/RNA and AllPrep FFPE DNA/RNA Mini Kits (Qiagen), respectively. DNA quantification and integrity were assessed using Qubit dsDNA BR Assay Kit in Qubit 4.0 (ThermoFisher Scientific) and a 4200 TapeStation system (Agilent).

134

135 2.3. RetroTest method: design, library construction and target sequencing

During L1 transcription, the processing machinery sometimes bypasses the L1 polyadenylation signal until a second 3' downstream polyadenylation site, mobilizing unique sequences downstream of the element in a process called *L1 3' transduction*. This process has been reported to occur in around 10% of the L1 mobilizations [7] and can be used as an indirect measurement of real active L1 elements. Accordingly, there are three different types of retrotranspositions: solo-

142 L1 (TD0), when a partial or complete L1 is retrotransposed; partnered 143 transductions (TD1), in which a L1 and downstream unique sequence are 144 retrotransposed; and orphan transductions (TD2), in which only the unique 145 sequence downstream of the active L1 is mobilized without the associated L1 [7]. 146 RetroTest is based on targeted sequencing, where the capture probes are designed 147 against the unique sequence downstream of the 124 L1 full-length competent 148 elements previously described [7] using SureSelect design from Agilent. RetroTest 149 identifies L1 TD2 orphan insertions through the detection of discordant reads and 150 clipped reads. The main idea behind the method is that discordant read pairs, 151 where one of the mates is mapped to a L1 3' downstream sequence while the other 152 is mapped to the insertion target sequence, support an insertion. In addition, 153 clipped reads, mapped to the target sequence but containing a discordant extreme 154 blatting to a L1 3' downstream sequence, are detected to identify the breakpoint of 155 the insertion (Fig. 1A). Here, a minimum size of 2 reads per cluster and a minimum 156 of 4 supporting reads was specified to call a L1 insertion (Additional file 1).

Target libraries were constructed with SureSelect Target Enrichment System for Illumina Paired-End Multiplexed Sequencing (Agilent). 100 ng of gDNA from each sample were sheared using a Covaris M220 Focused-Ultrasonicator (Covaris) and libraries and capture with targeted RNA baits were performed. The multiplexed samples were sequenced with Illumina 150bp paired-end.

162 Sequencing reads were mapped to the hg19 reference genome by Burrows-163 Wheeler Aligner BWA-mem [13]. Samtools [14] was used to sort the aligned reads 164 and to index the obtained bam file, applying Bammarkduplicates2 from Picard 165 tools [15] to mark duplicated reads.

166

#### 167 2.4. RetroTest benchmarking

We generated simulated paired-end read datasets using ART [16] and several
commands from MEIGA-MEIsimulator, an in-house bioinformatic tool (Additional
file 1).

171 To mimic the capture process, we selected read pairs with at least one of the mates 172 mapping on a given set of target regions with Picard FilterSamReads v2.18.14 [15]. 173 We used the resulting bam files to assess sensitivity and specificity under different 174 conditions. To test how our method performs with subclonal events, we simulated 175 transductions at different VAFs (10%, 20%, 40% and 50%). We also studied how 176 coverage affects the detection power of our algorithm. Using Picard 177 DownSampleSam v2.18.14 [15], we subsampled reads from a 150x simulation at 178 50% VAF under different sequencing depths (15x, 30x, 60x, 90x, 120x and 150x).

179 We compared RetroTest performance with Transposon Finder in Cancer (TraFiC), used previously to explore somatic retrotransposition in PCAWG [7]. Both were 180 181 used to call the simulated events. Precision was calculated dividing the number of 182 true positive calls by the number of total calls performed by the method. Recall 183 was calculated dividing the number of true positive calls by the number of total 184 simulated events. True positives, False positives and False negatives were 185 identified by intersecting the coordinates of simulated events with the coordinates 186 of the calls using BEDTools intersect [17]. To compare RetroTest and TraFiC 187 results, Venn diagrams with the insertions detected by each method were plotted by using vennDiagram R package. 188

189

190 2. 5. Whole Genome Sequencing and determination of mutation profile.

To obtain WGS data, DNA was sent to an external service (Macrogen). Truseq Nano
DNA Libraries (350bp) were constructed and sequenced in a NovaSeq6000
Illumina platform (150bp paired-end). For a detailed explanation see Additional
File 1.

195

196 2.6. Statistical analyses

The association between L1 transduction rate (corrected by coverage) and patient clinical features was assessed by multiple linear regressions. Wilcoxon or Fisher test, depending on sample size, were applied to compare the differences in mean values for clinical variables. Overall survival (OS), progression free survival (PFS) and survival probability analyses were performed with the *survminer* and *survival* R packages, using log-rank test to compare different groups. The association between survival and clinical variables was evaluated by Cox regression.

204

205 2.7. Enrichment analysis

All enrichment analyses were performed using *enrichR* R package [18]. Thecomplete list of pathways databases can be found in Additional File 1.

208

### 210 3. Results

#### 211 3.1. RetroTest Benchmarking

212 During L1 transcription, transductions are reported to occur in around 10% of the 213 L1 mobilizations [7], moving also unique sequences downstream of the source 214 element. RetroTest is designed to capture these mobilized and downstream-215 transduced unique sequences from orphan transductions (TD2) and use them as 216 barcodes (Fig. 1A). These barcodes can identify unequivocally the insertions 217 caused by these 124 L1 source elements active in cancer [7,9]. With this aim, we 218 focused RetroTest probe design on the first 5000 nucleotides adjacent to the L1 3' 219 regions for each of the 124 L1 source elements, since these are the regions most 220 frequently transduced [7]. Since RetroTest uses transductions as an indirect 221 measure of real L1 activation, we first compared L1 activation versus TD2 using the 222 whole PCAWG data. In this way, we confirmed a high and statistically significant 223 correlation between both events (r=0.88,  $p=2.2e^{-16}$ ), and a relation of 1:10 as 224 previously described (Fig. 1B).

225 Next, we optimized the lab protocol for both FFPE and fresh-frozen tissues and 226 developed an associated bioinformatic pipeline. We evaluated the performance 227 and accuracy of RetroTest in detecting L1 activation by generating an artificial 228 cancer genome. In this genome, we have randomly distributed a total of 2480 L1 229 transductions. Using simulations, we assessed the performance of RetroTest for 230 different sequencing depth: 15x, 30x, 60x, 90x, 120x and 150x. RetroTest obtained 231 a precision around 0.99 in all cases and a recall around 0.96 (Fig. 1C). We also 232 evaluated the variation of the performance depending on the variant allele 233 frequency (VAF) of the integrations, precisely for the following VAFs: 10%, 20%, 234 40% and 50%. In this case, RetroTest obtained a precision around 1, decreasing

for lower VAFs, and a recall ranged from 0.81 to 0.96, augmenting as increasing theVAF (Fig. 1D).

237 Then, we compared RetroTest and the classical TraFiC, used for WGS in PCAWG 238 [7]. As TraFiC is designed to work only with standard WGS 30x data, we compared 239 the analysis varying exclusively the VAFs. TraFiC precision ranged from 0.99 to 240 0.88 and recall ranged from 0.11 to 0.87 as VAF increased (although the maximum 241 recall was obtained for VAFs of 40%, being 0.87) (Fig. 1E) (Additional File 2: Table 242 S1). We compared the performance of both methods by intersecting both calls in 243 the mock tumor genome. Using a VAF of 50%, most of the variants were called by 244 both methods, concretely 2216 variants, while RetroTest exclusively called 167, 245 and TraFiC 33 private events, most of them resulting in false positives according to 246 IGV (Fig. 1F).

247

248 *3.2. L1 activation in HNSCC* 

249 Once confirmed the accuracy and precision of RetroTest, we decided to apply it to 250 a more extensive HNSCC cohort, composed of 96 tumors along the tumor stages, 251 from T1 to T4 (Table 1). We detected L1 activation in 75% of the patients (Fig. 2A), 252 out of which 48.6% showed high activity (beyond the median) (Table 2). When the 253 activation was studied along the different tumor stages of the disease, advanced 254 disease (T3-T4) showed statistically higher L1 activation compared with early 255 stages (T1-T2) (p=0.0072) (Fig. 2B). Following tumor staging, L1 activation was 256 detected in 62.5% of T1 tumors, 63.1% of T2 tumors, 94.4% of T3 tumors, and 257 73.5% of the tumors in T4 (Table 2). The detection of L1 activation in all the tumor 258 stages among the different patients, even in the first stage of the disease (T1), 259 supports an early L1 activation during tumor progression.

260 Then, we analyzed L1 activation considering different patients' clinical 261 characteristics, finding no statistically significant association between the L1 262 activation and alcohol consumption (p=0.14) or sex (p=0.055). Interestingly, 263 smoker patients showed statistically significantly higher L1 activity than non-264 smokers (p=0.0015) (Fig. 2C). We did not find an association between L1 265 activation and survival probability (p=0.59 active vs. inactive, p=0.49 high vs. low 266 rate) (Additional File 3: Fig. S1), although when considering those T1 patients who 267 have L1 already active at early stages, Kaplan-Meier curve showed that they tend 268 to have a lower survival probability, not being statistically significant (p=0.43) 269 (Fig. 2D).

Finally, in addition to localizing the position of each transduction, RetroTest can also identify the source L1 element that has been mobilized. Thus, we have detected L1 transductions in 23 genes throughout 27 patients. As shown in Fig. 2E, most of these insertions are caused by a few source elements that resulted very active in HNSCC, especially the 22q12.1.

275

#### 276 3.3. HNSCC mutation profile and L1 activation

277 To further characterize the molecular profile of L1 activation in our HNSCC cohort, 278 we obtained WGS data from 19 tumor samples from patients measured by 279 RetroTest. To detect only somatic variation, their corresponding paired-normal 280 samples were included as germline control. We detected a median of 40 single 281 nucleotide variants (SNVs) and INDELs, identifying a total of 1012 somatic variants 282 throughout the cohort, affecting 918 genes (Additional File 2: Table S2). As shown in Fig. 3A, we did not detect a correlation between L1 activation and the general 283 284 tumor mutation burden (TMB). Our results showed that the most frequently

285 mutated gene was TP53 (36.8%), followed by NOTCH1 (26.3%), MT-ND5 (26.3%), 286 *FAT1*, and *GRIN2A* (21.1%). Interestingly, we found that most of the patients with TP53 mutations showed also high L1 activity (71.4%). In fact, when we compared 287 288 the L1 activation with the TP53 mutation, we found a clear association (p=0.056) 289 (Fig. 3B). Enrichment analyses with the mutated genes showed involved key 290 processes for cancer progression such as Notch signaling, TGFß signaling, and 291 again *p53 activity regulation* (Fig. 3C) (Additional File 2: Table S3). CHEA analysis 292 revealed the alteration of transcription factors related to epigenetic mechanisms 293 including Polycomb members (*EZH2, SUZ12*) (Fig. 3D) (Additional File 2: Table S4). 294

295 3.4. Profiling normal adjacent tissues to the HNSCC tumor (NAT)

296 To further understand the early HNSCC features, we decided to evaluate a possible 297 field cancerization process, in which the normal cell population is replaced by 298 cancer-primed cells, without anatomical or morphological changes, but being already premalignant at molecular level. To this, we analyzed the available normal 299 300 samples obtained from adjacent tissues to the tumor and the peripheral blood 301 mononuclear cells (PBMCs), used as germline control (Fig. 4A). We detected a total 302 of 25 high impact and/or possibly pathogenic somatic variants affecting the NAT 303 (Additional File 2: Table S5). Most of these specific mutations (n=20; 80%) were 304 exclusive from NAT tissue, including those affecting key genes such as NOTCH1 305 (the most mutated gene), FAT1 or PPARD; while 20% were shared between NAT 306 and tumor tissue, affecting genes such as CDKN2A.

To elucidate whether L1 further supports field cancerization, we evaluated the
NAT of a total of 9 patients by RetroTest. We compared the L1 elements active in
the tumor, in the NAT, and in their corresponding paired germline. In this way, we

could confirm that most of the L1 activation was present only in the tumor, 5
insertions resulted germline, and 1 element appeared active and shared by tumor
and NAT. Surprisingly, 4 insertions appeared exclusively in NAT (Fig. 4B). Thus, we
could confirm field cancerization and demonstrate that L1 is already active in NAT,
supporting once again its early activation in HNSCC.

315

#### 316 4. Discussion

317 Since the recently demonstrated high impact of L1 in cancer genomes [7,9], L1 has 318 been evaluated as a cancer biomarker in different studies assessing its activity by 319 evaluating L1 methylation, RNA expression, or protein levels [19-22]. However, 320 most of L1 genome sequences are truncated and not functional, so results can 321 present important biases in their L1 estimations, while its translation into clinical 322 routine can be challenging due to RNA/protein instability. Previous proposed 323 technologies based on DNA full-length L1 retrotransposon capture sequencing, 324 such as RC-seq [23], present the associated possible bias of the real L1 activation, 325 besides only offer global L1 estimates, and important DNA requirements (2.5µg 326 starting genomic DNA), unaffordable for clinical practice. The most recent 327 approaches are based on the identification of L1 insertions as real L1 activation 328 measure (TraFiC [7], xTea [24], MELT [25] and Mobster [26]). They use Whole 329 Genome or Whole Exome Sequencing from Illumina pair-end short reads, nevertheless, short reads hamper the detection of transposable elements 330 331 insertions in highly repetitive or complex rearrangement regions. Additionally, 332 these high throughput approaches are not affordable for most of the hospitals. 333 More recently, long reads sequencing has arisen as a new possibility (xTea [24], 334 PALMER [27]), but again their requirements of huge amounts of high-quality DNA

335 remain unaffordable for biopsies mainly composed of small samples and 336 fragmented DNA. Thus, incorporating L1 activation into the clinical practice 337 requires new methods supported by standardization and rigorous validation to 338 demonstrate its utility.

339 Here, we present RetroTest: a new method to detect real L1 activation in clinical 340 samples with low DNA input requirements, both from fresh/frozen or FFPE 341 biopsies. Its novelty and power lie in the targeted detection of active source L1 342 elements, which showed a highly and direct statistical correlation with total L1 343 activity (as demonstrated by our data) in a more cost-effective than previously 344 proposed approaches. Our method not only offers global L1 estimates but also 345 identifies the L1 elements active in each real sample. Our benchmarking supports 346 the high precision (1) and recall of RetroTest (0.81-0.96), improving according to 347 coverage, even reaching the possibility of detecting subclonal insertions. The high 348 coincidence in the variants called by TraFic and RetroTest, in both simulations and 349 real-world data, supports the high potential for this new methodology.

350 L1 somatic retrotransposition was previously demonstrated as the second most 351 frequent type of structural variants among HNSCC genomes [9]. Accordingly, our 352 results demonstrate that most HNSCC patients (75%) present L1 activation, even 353 near half of them with high levels (49%). The activation was higher in late stages, 354 as found in Barret's esophagus, where lower L1 activity was detected in the early 355 stages increasing with cancer progression [28]. Interestingly, we found a 356 surprisingly early activation already in the first stages of HNSCC, with activation of 357 L1 in 62-63% of the T1 patients. These data pointed towards L1 activation as an early event in the configuration of HNSCC genomes and, thus, in the development 358

of the disease. In fact, those stage T1 patients with L1 activation tended to presenta lower OS.

361 We found an association between high L1 activity and smoking habits. Previous 362 studies had reported higher hypomethylation rates of L1 in smokers [29], even in 363 non-cancerous epithelial tissues [30]. Considering that around 75% of HNSCC are 364 associated with tobacco [31], this mechanism could be responsible for the high L1 365 activity levels in HNSCC, since methylation is one of the best-demonstrated 366 mechanisms preventing L1 reactivation [7,32]. In fact, L1 hypomethylation has 367 been associated with worse prognosis in HNSCC, including a higher risk of relapse 368 [33–35]. This hypomethylation has been found as an early event in CRC, gastric 369 and oral cancer [36–39]. Interestingly, it was reported that L1 methylation levels 370 were significantly lower in oral premalignant lesions of patients who then 371 developed oral cancer [39].

The source element L1 most active in our cohort was that at 22q12.1, coincident with our previous results [7, 10]. This L1 is located antisense to an intron of the TTC28 gene and has been also recently identified as the intact LINE-1 mRNA most highly expressed in breast, ovarian and colon cancer [40], and the L1 element accounting for most transductions in colorrectal cancer [33], supporting the same hottest activity in HNSCC.

Our WGS analyses confirmed no correlation between L1 activity and TMB, but an association between *TP53* mutation and L1 activation, in line with previous studies suggesting that *TP53* can repress L1 mobilization [9,40–43]. We also identified an important epigenetic regulation among the transcription factors strongly interacting with the mutated genes, specially related to repressive complex Polycomb. Intriguingly, Mangoni et al. have just deciphered that L1 RNAs can act as

long non-coding RNAs and directly interact with the Polycomb during brain development and evolution [44]. We also reported previously that Polycomb could regulate lncRNA *HOTAIR* in bladder cancer [45]. In the same sense, Ishak et al. demonstrated an EZH2-dependent silencing of genomic repeat sequences, including L1 elements [46]. Therefore, additional analyses would be required to further address if this epigenetic network plays a role in cancer genome reorganization.

391 Then, to evaluate possible HNSCC early diagnosis potential biomarkers is 392 fundamental to get insights into the transition from pre-tumoral to cancer disease. 393 Thus, we evaluated the presence of field cancerization and identified genetic 394 features that can eventually lead to cancer development [47], finding exclusive 395 somatic mutations in the NAT and a small proportion shared with the tumor. 396 Several studies have recently described patchworks of different clones in normal 397 tissues, some of them even bearing driver mutations, increasing with age or 398 smoking habits [48–50]. We found NOTCH1 and FAT1 as the most mutated genes, 399 as Martincorena's results in normal skin and esophagus [48,51]. These genes 400 showed also high mutation rates in the tumor, indicating the presence of a 401 precancerous or cancer invasion field.

Finally, when we evaluated L1 activity, several mobilizations were exclusively found in NAT, and only one appeared shared with the tumor, again supporting a cancerization field. Somatic L1 retrotransposition events have been recently described in normal urothelium and colorectal epithelium, although with much lower rates than in bladder and colorectal cancer [52,53]. L1 activity has been also described in a few pre-tumor samples including Barrett's esophagus and colorectal adenomas [8,28,54]. Therefore, L1 activation arises as a reinforced early event,

409 even in pre-tumor stages, in the natural history of HNSCC, with the associated410 potential of L1 as a field cancerization biomarker.

411

#### 412 **Conclusions**

We present the development and benchmarking of RetroTest, which allows an easy measurement of real L1 activation from small tumor biopsies with high efficacy, favoring its implementation in real clinical settings. RetroTest revealed that most of the HNSCC patients present L1 activation, associated with smoking habits and already active in early stages of the disease and NAT, supporting a field cancerization process and its potential as early diagnostic biomarker.

419

#### 420 Acknowledgements

421 Authors thank all the enrolled patients and their families. This research project 422 was made possible through the access granted by the Galician Supercomputing 423 Center (CESGA) to its supercomputing infrastructure. The supercomputer 424 FinisTerrae III and its permanent data storage system have been funded by the 425 Spanish Ministry of Science and Innovation, the Galician Government and the 426 European Regional Development Fund (ERDF).

This work was supported by the Instituto de Salud Carlos III (ISCIII) and the European Social Fund ("Investing in your future") (PI19/01113, and partially by P121/00208, co-funded by FEDER and the European Union), and the Spanish Association Against Cancer Scientific Foundation (IDEAS19122MART). A.O. was supported by a predoctoral fellowship from the Galician Innovation Agency, Xunta de Galicia (ED481A-2020/214). M.M.-F. and J.B. were previously supported by the Spanish Association Against Cancer Scientific Foundation (INVES207MART and

434	PRDCR19007BREA_001, respectively). M.MF. is currently supported by the
435	Miguel Servet program (CP20/00188) from the Instituto de Salud Carlos III (ISCIII)
436	and the European Social Fund ("Investing in your future"). M.G-G. is supported by a
437	postdoctoral fellowship from the Galician Innovation Agency, Xunta de Galicia
438	(IN606B-2024/014).
439	
440	Ethics statement
441	The Ethical Committee for Clinical Research of Santiago-Lugo gave ethical approval
442	for this work (CEIC 2018/567).
443	
444	Competing interests
445	The authors declare no competing interests.
446	
447	Consent for publication
448	All authors give consent for the publication of this manuscript.
449	
450	Data availability statement
451	Whole Genome Sequencing data from the HNSCC cohort is deposited into the
452	Sequence Read Archive (SRA) repository under the following BioProject ID:
453	PRJNA1053897. RetroTest pipeline is publicly available at
454	https://gitlab.com/mobilegenomesgroup/RETROTEST.
455	
456	CRediT authorship contribution statement
457	

458 Software, Data curation, Investigation, Validation, Visualization, Writing – review

459 and editing. Sonia Zumalave: Conceptualization, Investigation, Methodology, 460 Software, Validation, Writing – review and editing. **Bernardo Rodríguez-Martin**: 461 Methodology, Software. Conceptualization, María **Gallardo-Gómez**: 462 Conceptualization, Visualization, Writing – review and editing. Martin 463 Santamarina: Methodology, Validation. **Pequeño-Valtierra:** Ana 464 Conceptualization, Investigation. Laura Juaneda-Magdalena: Methodology, Conceptualization, Writing - review and editing. Ramón García-Escudero: 465 466 Methodology, Writing - review and editing. Jose Luis López-Cedrún: 467 Funding acquisition. Methodology. Máximo Fraga: Iosé MC **Tubio**: 468 Conceptualization, Funding acquisition. Mónica Martínez-Fernández: Writing -469 review & editing, Writing – original draft, Supervision, Resources, Investigation, 470 Project administration, Funding acquisition, Conceptualization. All authors approved the final version. 471

472

#### 473 References

474	[1]	H.H. Kazazian, J. V. Moran, The impact of L1 retrotransposons on the human
475		genome, Nat. Genet. 19 (1998) 19–24. https://doi.org/10.1038/NG0598-19.
476	[2]	E.S. Lander, L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K.
477		Devon, K. Dewar, M. Doyle, W. Fitzhugh, R. Funke, D. Gage, K. Harris, A.
478		Heaford, J. Howland, L. Kann, J. Lehoczky, R. Levine, P. McEwan, K.
479		McKernan, J. Meldrim, J.P. Mesirov, C. Miranda, W. Morris, J. Naylor, C.
480		Raymond, M. Rosetti, R. Santos, A. Sheridan, C. Sougnez, N. Stange-Thomann,
481		N. Stojanovic, A. Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough,
482		S. Beck, D. Bentley, J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P.
483		Deloukas, A. Dunham, I. Dunham, R. Durbin, L. French, D. Grafham, S.

484	Gregory, T. Hubbard, S. Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray,
485	L. Matthews, S. Mercer, S. Milne, J.C. Mullikin, A. Mungall, R. Plumb, M. Ross,
486	R. Shownkeen, S. Sims, R.H. Waterston, R.K. Wilson, L.W. Hillier, J.D.
487	McPherson, M.A. Marra, E.R. Mardis, L.A. Fulton, A.T. Chinwalla, K.H. Pepin,
488	W.R. Gish, S.L. Chissoe, M.C. Wendl, K.D. Delehaunty, T.L. Miner, A.
489	Delehaunty, J.B. Kramer, L.L. Cook, R.S. Fulton, D.L. Johnson, P.J. Minx, S.W.
490	Clifton, T. Hawkins, E. Branscomb, P. Predki, P. Richardson, S. Wenning, T.
491	Slezak, N. Doggett, J.F. Cheng, A. Olsen, S. Lucas, C. Elkin, E. Uberbacher, M.
492	Frazier, R.A. Gibbs, D.M. Muzny, S.E. Scherer, J.B. Bouck, E.J. Sodergren, K.C.
493	Worley, C.M. Rives, J.H. Gorrell, M.L. Metzker, S.L. Naylor, R.S. Kucherlapati,
494	D.L. Nelson, G.M. Weinstock, Y. Sakaki, A. Fujiyama, M. Hattori, T. Yada, A.
495	Toyoda, T. Itoh, C. Kawagoe, H. Watanabe, Y. Totoki, T. Taylor, J.
496	Weissenbach, R. Heilig, W. Saurin, F. Artiguenave, P. Brottier, T. Bruls, E.
497	Pelletier, C. Robert, P. Wincker, A. Rosenthal, M. Platzer, G. Nyakatura, S.
498	Taudien, A. Rump, D.R. Smith, L. Doucette-Stamm, M. Rubenfield, K.
499	Weinstock, M.L. Hong, J. Dubois, H. Yang, J. Yu, J. Wang, G. Huang, J. Gu, L.
500	Hood, L. Rowen, A. Madan, S. Qin, R.W. Davis, N.A. Federspiel, A.P. Abola, M.J.
501	Proctor, B.A. Roe, F. Chen, H. Pan, J. Ramser, H. Lehrach, R. Reinhardt, W.R.
502	McCombie, M. De La Bastide, N. Dedhia, H. Blöcker, K. Hornischer, G.
503	Nordsiek, R. Agarwala, L. Aravind, J.A. Bailey, A. Bateman, S. Batzoglou, E.
504	Birney, P. Bork, D.G. Brown, C.B. Burge, L. Cerutti, H.C. Chen, D. Church, M.
505	Clamp, R.R. Copley, T. Doerks, S.R. Eddy, E.E. Eichler, T.S. Furey, J. Galagan,
506	J.G.R. Gilbert, C. Harmon, Y. Hayashizaki, D. Haussler, H. Hermjakob, K.
507	Hokamp, W. Jang, L.S. Johnson, T.A. Jones, S. Kasif, A. Kaspryzk, S. Kennedy,
508	W.J. Kent, P. Kitts, E. V. Koonin, I. Korf, D. Kulp, D. Lancet, T.M. Lowe, A.

509		McLysaght, T. Mikkelsen, J. V. Moran, N. Mulder, V.J. Pollara, C.P. Ponting, G.
510		Schuler, J. Schultz, G. Slater, A.F.A. Smit, E. Stupka, J. Szustakowki, D. Thierry-
511		Mieg, J. Thierry-Mieg, L. Wagner, J. Wallis, R. Wheeler, A. Williams, Y.I. Wolf,
512		K.H. Wolfe, S.P. Yang, R.F. Yeh, F. Collins, M.S. Guyer, J. Peterson, A.
513		Felsenfeld, K.A. Wetterstrand, R.M. Myers, J. Schmutz, M. Dickson, J.
514		Grimwood, D.R. Cox, M. V. Olson, R. Kaul, C. Raymond, N. Shimizu, K.
515		Kawasaki, S. Minoshima, G.A. Evans, M. Athanasiou, R. Schultz, A. Patrinos,
516		M.J. Morgan, Initial sequencing and analysis of the human genome, Nature
517		409 (2001) 860–921. https://doi.org/10.1038/35057062.
518	[3]	C.R. Beck, P. Collier, C. Macfarlane, M. Malig, J.M. Kidd, E.E. Eichler, R.M.
519		Badge, J. V. Moran, LINE-1 retrotransposition activity in human genomes,
520		Cell 141 (2010) 1159–1170.
521	[4]	B. Brouha, J. Schustak, R.M. Badge, S. Lutz-Prigge, A.H. Farley, J. V. Morant,
522		H.H. Kazazian, Hot L1s account for the bulk of retrotransposition in the
523		human population, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5280–5285.
524	[5]	S.J. Hoyt, J.M. Storer, G.A. Hartley, P.G.S. Grady, A. Gershman, L.G. de Lima, C.
525		Limouse, R. Halabian, L. Wojenski, M. Rodriguez, N. Altemose, A. Rhie, L.J.
526		Core, J.L. Gerton, W. Makalowski, D. Olson, J. Rosen, A.F.A. Smit, A.F. Straight,
527		M.R. Vollger, T.J. Wheeler, M.C. Schatz, E.E. Eichler, A.M. Phillippy, W. Timp,
528		K.H. Miga, R.J. O'Neill, From telomere to telomere: The transcriptional and
529		epigenetic state of human repeat elements, Science. 376 (2022).
530		https://doi.org/10.1126/science.abk3112.
531	[6]	D.M. Sassaman, B.A. Dombroski, J. V. Moran, M.L. Kimberland, T.P. Naas, R.J.
532		DeBerardinis, A. Gabriel, G.D. Swergold, H.H. Kazazian, Many human L1
533		elements are capable of retrotransposition, Nat. Genet. 16 (1997) 37–43.

534 [7] J.M.C. e. al Tubio, Extensive transduction of nonrepetitive DNA	mediated by
---	-------------

535 L1retrotransposition in cancer genomes, Science. 345 (2014) 1251343.

536 https://doi.org/10.1126/science.1251343.Extensive.

- 537 [8] A.D. Ewing, A. Gacita, L.D. Wood, F. Ma, D. Xing, M.S. Kim, S.S. Manda, G. Abril,
- 538 G. Pereira, A. Makohon-Moore, L.H.J. Looijenga, A.J.M. Gillis, R.H. Hruban, R.A.
- 539 Anders, K.E. Romans, A. Pandey, C.A. Iacobuzio-Donahue, B. Vogelstein, K.W.
- 540 Kinzler, H.H. Kazazian, S. Solyom, Widespread somatic L1 retrotransposition
- 541 occurs early during gastrointestinal cancer evolution, Genome Res. 25
- 542 (2015) 1536–1545. https://doi.org/10.1101/gr.196238.115.
- 543 [9] B. Rodriguez-Martin, E.G. Alvarez, A. Baez-Ortega, J. Zamora, F. Supek, J.

544 Demeulemeester, M. Santamarina, Y.S. Ju, J. Temes, D. Garcia-Souto, H.

- 545 Detering, Y. Li, J. Rodriguez-Castro, A. Dueso-Barroso, A.L. Bruzos, S.C.
- 546 Dentro, M.G. Blanco, G. Contino, D. Ardeljan, M. Tojo, N.D. Roberts, S.
- 547 Zumalave, P.A.W. Edwards, J. Weischenfeldt, M. Puiggròs, Z. Chong, K. Chen,
- 548 E.A. Lee, J.A. Wala, K. Raine, A. Butler, S.M. Waszak, F.C.P. Navarro, S.E.
- 549 Schumacher, J. Monlong, F. Maura, N. Bolli, G. Bourque, M. Gerstein, P.J. Park,
- 550 D.C. Wedge, R. Beroukhim, D. Torrents, J.O. Korbel, I.I. Martincorena, R.C.
- 551 Fitzgerald, P. Van Loo, H.H. Kazazian, K.H. Burns, K.C. Akdemir, E.G. Alvarez,
- 552 A. Baez-Ortega, R. Beroukhim, P.C. Boutros, D.D.L. Bowtell, B. Brors, K.H.
- 553 Burns, P.J. Campbell, K. Chan, I. Cortés-Ciriano, A. Dueso-Barroso, A.J.
- 554 Dunford, P.A.W. Edwards, X. Estivill, D. Etemadmoghadam, L. Feuerbach, J.L.
- 555 Fink, M. Frenkel-Morgenstern, D.W. Garsed, M. Gerstein, D.A. Gordenin, D.
- 556 Haan, J.E. Haber, J.M. Hess, B. Hutter, M. Imielinski, D.T.W. Jones, M.D.
- 557 Kazanov, L.J. Klimczak, Y. Koh, J.O. Korbel, K. Kumar, E.A. Lee, J.J.K. Lee, Y. Li,
- 558 A.G. Lynch, G. Macintyre, F. Markowetz, A. Martinez-Fundichely, M.

559		Meyerson, S. Miyano, H. Nakagawa, F.C.P. Navarro, S. Ossowski, J. V. Pearson,
560		J. V. Pearson, K. Rippe, N.D. Roberts, S.A. Roberts, B. Rodriguez-Martin, B.
561		Rodriguez-Martin, S.E. Schumacher, M. Shackleton, N. Sidiropoulos, L.
562		Sieverling, C. Stewart, J.M.C. Tubio, I. Villasante, N. Waddell, J.A. Wala, J.
563		Weischenfeldt, L. Yang, X. Yao, S.S. Yoon, J. Zamora, C.Z. Zhang, P.J. Campbell,
564		J.M.C. Tubio, S.E. Schumacher, R. Scully, B. Rodriguez-Martin, Y.S. Ju, M.D.
565		Kazanov, L.J. Klimczak, Y. Koh, J.O. Korbel, K. Kumar, E.A. Lee, J.J.K. Lee, Y. Li,
566		A.G. Lynch, G. Macintyre, F. Markowetz, I.I. Martincorena, A. Martinez-
567		Fundichely, M. Meyerson, S. Miyano, H. Nakagawa, F.C.P. Navarro, S.
568		Ossowski, J. V. Pearson, M. Puiggròs, K. Rippe, N.D. Roberts, S.A. Roberts, B.
569		Rodriguez-Martin, S.E. Schumacher, R. Scully, M. Shackleton, N. Sidiropoulos,
570		L. Sieverling, C. Stewart, J.M.C. Tubio, I. Villasante, N. Waddell, J.A. Wala, J.
571		Weischenfeldt, L. Yang, X. Yao, S.S. Yoon, J. Zamora, C.Z. Zhang, P.J. Campbell,
572		J.M.C. Tubio, Pan-cancer analysis of whole genomes identifies driver
573		rearrangements promoted by LINE-1 retrotransposition, Nat. Genet. 52
574		(2020) 306–319. https://doi.org/10.1038/s41588-019-0562-0.
575	[10]	A. Jou, J. Hess, Epidemiology and Molecular Biology of Head and Neck
576		Cancer, Oncol. Res. Treat. 40 (2017) 328–332.
577		https://doi.org/10.1159/000477127.
578	[11]	M. Plath, J. Gass, M. Hlevnjak, Q. Li, B. Feng, X.P. Hostench, M. Bieg, L.
579		Schroeder, D. Holzinger, M. Zapatka, K. Freier, W. Weichert, J. Hess, K. Zaoui,
580		Unraveling most abundant mutational signatures in head and neck cancer,
581		Int. J. Cancer 148 (2021) 115–127. https://doi.org/10.1002/IJC.33297.
582	[12]	C.R. Leemans, B.J.M. Braakhuis, R.H. Brakenhoff, The molecular biology of
583		head and neck cancer, Nat. Rev. Cancer 11 (2011) 9–22.

- 584 https://doi.org/10.1038/nrc2982.
- 585 H. Li, Aligning sequence reads, clone sequences and assembly contigs with [13]
- 586 BWA-MEM, ArXiv: Genomics (2013).
- 587 https://doi.org/10.6084/M9.FIGSHARE.963153.V1.
- 588 [14] P. Danecek, J.K. Bonfield, J. Liddle, J. Marshall, V. Ohan, M.O. Pollard, A.
- 589 Whitwham, T. Keane, S.A. McCarthy, R.M. Davies, Twelve years of SAMtools
- 590 and BCFtools. Gigascience 10 (2021) 1-4.
- 591 https://doi.org/10.1093/GIGASCIENCE/GIAB008.
- 592 Broad Institute, Picard Tools, Http://Broadinstitute.Github.Io/Picard/ (n.d.). [15]
- 593 [16] W. Huang, L. Li, J.R. Myers, G.T. Marth, ART: a next-generation sequencing
- 594 read simulator, Bioinformatics 28 (2012) 593-594.
- 595 https://doi.org/10.1093/BIOINFORMATICS/BTR708.
- 596 A.R. Quinlan, I.M. Hall, BEDTools: a flexible suite of utilities for comparing [17] 597 genomic features, Bioinformatics 26 (2010) 841-842.
- https://doi.org/10.1093/BIOINFORMATICS/BTQ033.
- 599 [18] M. V. Kuleshov, M.R. Jones, A.D. Rouillard, N.F. Fernandez, O. Duan, Z. Wang,
- 600 S. Koplev, S.L. Jenkins, K.M. Jagodnik, A. Lachmann, M.G. McDermott, C.D.
- 601 Monteiro, G.W. Gundersen, A. Maayan, Enrichr: a comprehensive gene set
- 602 enrichment analysis web server 2016 update, Nucleic Acids Res. 44 (2016)
- 603 W90-W97. https://doi.org/10.1093/NAR/GKW377.
- 604 D. Ardeljan, M.S. Taylor, D.T. Ting, K.H. Burns, The Human Long Interspersed [19]
- 605 Element-1 Retrotransposon: An Emerging Biomarker of Neoplasia, Clin.
- 606 Chem. 63 (2017) 816-822.

- 607 https://doi.org/10.1373/CLINCHEM.2016.257444.
- 608 [20] M.L. Filipenko, U.A. Boyarskikh, L.S. Leskov, K. V. Subbotina, E.A. Khrapov, A.

609		V. Sokolov, I.S. Stilidi, N.E. Kushlinskii, The Level of LINE-1 mRNA Is
610		Increased in Extracellular Circulating Plasma RNA in Patients with
611		Colorectal Cancer, Bull. Exp. Biol. Med. 173 (2022) 261–264.
612		https://doi.org/10.1007/S10517-022-05530-2/METRICS.
613	[21]	S. Sato, M. Gillette, P.R. de Santiago, E. Kuhn, M. Burgess, K. Doucette, Y. Feng,
614		C. Mendez-Dorantes, P.J. Ippoliti, S. Hobday, M.A. Mitchell, K. Doberstein, S.M.
615		Gysler, M.S. Hirsch, L. Schwartz, M.J. Birrer, S.J. Skates, K.H. Burns, S.A. Carr,
616		R. Drapkin, LINE-1 ORF1p as a candidate biomarker in high grade serous
617		ovarian carcinoma, Sci. Rep. 13 (2023). https://doi.org/10.1038/s41598-
618		023-28840-5.
619	[22]	M.S. Taylor, C. Wu, P.C. Fridy, S.J. Zhang, Y. Senussi, J.C. Wolters, T. Cajuso, W
620		C. Cheng, J.D. Heaps, B.D. Miller, K. Mori, L. Cohen, H. Jiang, K.R. Molloy, B.T.
621		Chait, M.G. Goggins, I. Bhan, J.W. Franses, X. Yang, ME. Taplin, X. Wang, D.C.
622		Christiani, B.E. Johnson, M. Meyerson, R. Uppaluri, A.M. Egloff, E.N. Denault,
623		L.M. Spring, TL. Wang, IM. Shih, J.E. Fairman, E. Jung, K.S. Arora, O.H.
624		Yilmaz, S. Cohen, T. Sharova, G. Chi, B.L. Norden, Y. Song, L.T. Nieman, L.
625		Pappas, A.R. Parikh, M.R. Strickland, R.B. Corcoran, T. Mustelin, G. Eng, O.H.
626		Yilmaz, U.A. Matulonis, S.J. Skates, B.R. Rueda, R. Drapkin, S.J. Klempner, V.
627		Deshpande, D.T. Ting, M.P. Rout, J. LaCava, D.R. Walt, K.H. Burns,
628		Ultrasensitive detection of circulating LINE-1 ORF1p as a specific multi-
629		cancer biomarker, Cancer Discov. 13 (2023) OF1–OF16.
630		https://doi.org/10.1158/2159-8290.CD-23-
631		0313/729035/AM/ULTRASENSITIVE-DETECTION-OF-CIRCULATING-LINE-
632		1.
633	[23]	J.K. Baillie, M.W. Barnett, K.R. Upton, D.J. Gerhardt, T.A. Richmond, F. De

- 634 Sapio, P.M. Brennan, P. Rizzu, S. Smith, M. Fell, R.T. Talbot, S. Gustincich, T.C.
- 635 Freeman, J.S. Mattick, D.A. Hume, P. Heutink, P. Carninci, J.A. Jeddeloh, G.J.
- 636 Faulkner, Somatic retrotransposition alters the genetic landscape of the
- 637 human brain, Nature 479 (2011) 534–537.
- 638 https://doi.org/10.1038/nature10531.
- 639 [24] C. Chu, R. Borges-Monroy, V. V. Viswanadham, S. Lee, H. Li, E.A. Lee, P.J. Park,
- 640 Comprehensive identification of transposable element insertions using
- 641 multiple sequencing technologies, Nat. Commun. 12 (2021).

642 https://doi.org/10.1038/s41467-021-24041-8.

- 643 [25] E.J. Gardner, V.K. Lam, D.N. Harris, N.T. Chuang, E.C. Scott, W. Stephen
- 644 Pittard, R.E. Mills, S.E. Devine, The mobile element locator tool (MELT):
- 645 Population-scale mobile element discovery and biology, Genome Res. 27
- 646 (2017) 1916–1929. https://doi.org/10.1101/GR.218032.116/-/DC1.
- 647 [26] D.T. jwa. Thung, J. de Ligt, L.E.M. Vissers, M. Steehouwer, M. Kroon, P. de
- 648 Vries, E.P. Slagboom, K. Ye, J.A. Veltman, J.Y. Hehir-Kwa, Mobster: accurate
- 649 detection of mobile element insertions in next generation sequencing data,
- 650 Genome Biol. 15 (2014) 488. https://doi.org/10.1186/S13059-014-0488-
- 651 X/FIGURES/3.
- 652 [27] W. Zhou, S.B. Emery, D.A. Flasch, Y. Wang, K.Y. Kwan, J.M. Kidd, J. V. Moran,
- 653 R.E. Mills, Identification and characterization of occult human-specific LINE-
- 1 insertions using long-read sequencing technology, Nucleic Acids Res. 48
- 655 (2020) 1146–1163. https://doi.org/10.1093/NAR/GKZ1173.
- 656 [28] A.C. Katz-Summercorn, S. Jammula, A. Frangou, I. Peneva, M. O'Donovan, M.
- 657 Tripathi, S. Malhotra, M. di Pietro, S. Abbas, G. Devonshire, W. Januszewicz, A.
- 658 Blasko, K. Nowicki-Osuch, S. MacRae, A. Northrop, A.M. Redmond, D.C.

- 659 Wedge, R.C. Fitzgerald, Multi-omic cross-sectional cohort study of pre-
- 660 malignant Barrett's esophagus reveals early structural variation and
- 661 retrotransposon activity, Nat. Commun. 13 (2022).
- 662 https://doi.org/10.1038/s41467-022-28237-4.
- 663 [29] A.W. Caliri, A. Caceres, S. Tommasi, A. Besaratinia, Hypomethylation of LINE-
- 1 repeat elements and global loss of DNA hydroxymethylation in vapers and
- 665 smokers, Epigenetics 15 (2020) 816–829.
- 666 https://doi.org/10.1080/15592294.2020.1724401.
- 667 [30] H. Shigaki, Y. Baba, M. Watanabe, S. Iwagami, K. Miyake, T. Ishimoto, M.
- 668 Iwatsuki, H. Baba, LINE-1 hypomethylation in noncancerous esophageal
- mucosae is associated with smoking history, Ann. Surg. Oncol. 19 (2012)

670 4238-4243. https://doi.org/10.1245/s10434-012-2488-y.

- 671 [31] P. Vineis, M. Alavanja, P. Buffler, E. Fontham, S. Franceschi, Y.T. Gao, P.C.
- 672 Gupta, A. Hackshaw, E. Matos, J. Samet, F. Sitas, J. Smith, L. Stayner, K. Straif,
- 673 M.J. Thun, H.E. Wichmann, A.H. Wu, D. Zaridze, R. Peto, R. Doll, Tobacco and
- 674 cancer: recent epidemiological evidence, J. Natl. Cancer Inst. 96 (2004) 99–
- 675 106. https://doi.org/10.1093/JNCI/DJH014.
- 676 [32] K. Hur, P. Cejas, J. Feliu, J. Moreno-Rubio, E. Burgos, C.R. Boland, A. Goel,

677 Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to

678 activation of proto-oncogenes in human colorectal cancer metastasis, Gut 63

679 (2014) 635–646. https://doi.org/10.1136/GUTJNL-2012-304219.

- 680 [33] M. Casarotto, V. Lupato, G. Giurato, R. Guerrieri, S. Sulfaro, A. Salvati, E.
- 681 D'Angelo, C. Furlan, A. Menegaldo, L. Baboci, B. Montico, I. Turturici, R.
- 682 Dolcetti, S. Romeo, V. Baggio, S. Corrado, G. Businello, M. Guido, A. Weisz, V.
- 683 Giacomarra, G. Franchin, A. Steffan, L. Sigalotti, E. Vaccher, P. Boscolo-Rizzo,

684		P. Jerry, G. Fanetti, E. Fratta, LINE-1 hypomethylation is associated with poor
685		outcomes in locoregionally advanced oropharyngeal cancer, Clin.
686		Epigenetics 14 (2022). https://doi.org/10.1186/s13148-022-01386-5.
687	[34]	C. Furlan, J. Polesel, L. Barzan, G. Franchin, S. Sulfaro, S. Romeo, F. Colizzi, A.
688		Rizzo, V. Baggio, V. Giacomarra, A.P. Dei Tos, P. Boscolo-Rizzo, E. Vaccher, R.
689		Dolcetti, L. Sigalotti, E. Fratta, Prognostic significance of LINE-1
690		hypomethylation in oropharyngeal squamous cell carcinoma, Clin.
691		Epigenetics 9 (2017). https://doi.org/10.1186/S13148-017-0357-
692		Z/FIGURES/4.
693	[35]	K. Misawa, S. Yamada, M. Mima, T. Nakagawa, T. Kurokawa, A. Imai, D.
694		Mochizuki, D. Shinmura, T. Yamada, J. Kita, R. Ishikawa, Y. Yamaguchi, Y.
695		Misawa, T. Kanazawa, H. Kawasaki, H. Mineta, Long interspersed nuclear
696		element 1 hypomethylation has novel prognostic value and potential utility
697		in liquid biopsy for oral cavity cancer, Biomark. Res. 8 (2020) 1–10.
698		https://doi.org/10.1186/S40364-020-00235-Y/FIGURES/6.
699	[36]	A. Benard, C.J.H. Van De Velde, L. Lessard, H. Putter, L. Takeshima, P.J.K.
700		Kuppen, D.S.B. Hoon, Epigenetic status of LINE-1 predicts clinical outcome in
701		early-stage rectal cancer, Br. J. Cancer 109 (2013) 3073–3083.
702		https://doi.org/10.1038/bjc.2013.654.
703	[37]	E.J. Kim, W.C. Chung, D.B. Kim, Y.J. Kim, J.M. Lee, J.H. Jung, Y.K. Lee, Long
704		interspersed nuclear element (LINE)-1 methylation level as a molecular
705		marker of early gastric cancer, Dig. Liver Dis. 48 (2016) 1093–1097.
706		https://doi.org/10.1016/j.dld.2016.06.002.
707	[38]	E. Sunami, M. de Maat, A. Vu, R.R. Turner, D.S.B. Hoon, LINE-1
708		Hypomethylation During Primary Colon Cancer Progression, PLoS One 6

709		(2011) e18884. https://doi.org/10.1371/JOURNAL.PONE.0018884.
710	[39]	J.P. Foy, C.R. Pickering, V.A. Papadimitrakopoulou, J. Jelinek, S.H. Lin, W.N.
711		William, M.J. Frederick, J. Wang, W. Lang, L. Feng, L. Zhang, E.S. Kim, Y.H. Fan,
712		W.K. Hong, A.K. El-Naggar, J.J. Lee, J.N. Myers, J.P. Issa, S.M. Lippman, L. Mao,
713		P. Saintigny, New DNA methylation markers and global DNA
714		hypomethylation are associated with oral cancer development, Cancer Prev.
715		Res. 8 (2015) 1027–1035. https://doi.org/10.1158/1940-6207.CAPR-14-
716		0179.
717	[40]	W. McKerrow, X. Wang, C. Mendez-Dorantes, P. Mita, S. Cao, M. Grivainis, L.
718		Ding, J. LaCava, K.H. Burns, J.D. Boeke, D. Fenyö, LINE-1 expression in cancer
719		correlates with p53 mutation, copy number alteration, and S phase
720		checkpoint, Proc. Natl. Acad. Sci. U. S. A. 119 (2022).
721		https://doi.org/10.1073/PNAS.2115999119/-/DCSUPPLEMENTAL.
722	[41]	B. Tiwari, A.E. Jones, C.J. Caillet, S. Das, S.K. Royer, J.M. Abrams, P53 directly
723		represses human LINE1 transposons, Genes Dev. 34 (2020) 1439–1451.
724		https://doi.org/10.1101/GAD.343186.120/-/DC1.
725	[42]	P. Mita, X. Sun, D. Fenyö, D.J. Kahler, D. Li, N. Agmon, A. Wudzinska, S.
726		Keegan, J.S. Bader, C. Yun, J.D. Boeke, BRCA1 and S phase DNA repair
727		pathways restrict LINE-1 retrotransposition in human cells, Nat. Struct. Mol.
728		Biol. 27 (2020) 179–191. https://doi.org/10.1038/S41594-020-0374-Z.
729	[43]	N. Rodić, R. Sharma, R. Sharma, J. Zampella, L. Dai, M.S. Taylor, R.H. Hruban,
730		C.A. Iacobuzio-Donahue, A. Maitra, M.S. Torbenson, M. Goggins, I.M. Shih, A.S.
731		Duffield, E.A. Montgomery, E. Gabrielson, G.J. Netto, T.L. Lotan, A.M. De
732		Marzo, W. Westra, Z.A. Binder, B.A. Orr, G.L. Gallia, C.G. Eberhart, J.D. Boeke,
733		C.R. Harris, K.H. Burns, Long interspersed element-1 protein expression is a

734	hallmark of man	y human cancers, Am.	J. Pathol. 184 (	(2014) 1280-1286
		, ,		

- 735 https://doi.org/10.1016/j.ajpath.2014.01.007.
- 736 [44] D. Mangoni, A. Simi, P. Lau, A. Armaos, F. Ansaloni, A. Codino, D. Damiani, L.
- 737 Floreani, V. Di Carlo, D. Vozzi, F. Persichetti, C. Santoro, L. Pandolfini, G.G.
- 738 Tartaglia, R. Sanges, S. Gustincich, LINE-1 regulates cortical development by
- acting as long non-coding RNAs, Nat. Commun. 14 (2023).
- 740 https://doi.org/10.1038/s41467-023-40743-7.
- 741 [45] M. Martínez-Fernández, A. Feber, M. Dueñas, C. Segovia, C. Rubio, M.
- 742 Fernandez, F. Villacampa, J. Duarte, F.F. López-Calderón, M.J. Gómez-
- 743 Rodriguez, D. Castellano, J.L. Rodriguez-Peralto, F. De La Rosa, S. Beck, J.M.
- 744 Paramio, Analysis of the polycomb-related lncRNAs HOTAIR and ANRIL in
- 745bladder cancer, Clin. Epigenetics 7 (2015). https://doi.org/10.1186/s13148-
- 746 015-0141-x.
- 747 [46] C.A. Ishak, A.E. Marshall, D.T. Passos, C.R. White, J. Seung, M.J. Cecchini, S.
- 748 Ferwati, W.A. Macdonald, J. Christopher, I.D. Welch, S.M. Rubin, M.R.W.
- 749 Mann, F.A. Dick, An RB-EZH2 Complex Mediates Silencing of Repetitive DNA
- 750 Sequences, 64 (2017) 1074–1087.
- 751 https://doi.org/10.1016/j.molcel.2016.10.021.An.
- 752 [47] P. V. Angadi, J.K. Savitha, S.S. Rao, R.Y. Sivaranjini, Oral field cancerization:
- 753 Current evidence and future perspectives, Oral Maxillofac. Surg. 16 (2012)
- 754 171–180. https://doi.org/10.1007/S10006-012-0317-X/TABLES/1.
- 755 [48] I. Martincorena, A. Roshan, M. Gerstung, P. Ellis, P. Van Loo, S. McLaren, D.C.
- 756 Wedge, A. Fullam, L.B. Alexandrov, J.M. Tubio, L. Stebbings, A. Menzies, S.
- 757 Widaa, M.R. Stratton, P.H. Jones, P.J. Campbell, High burden and pervasive
- positive selection of somatic mutations in normal human skin, Science. 348

759		(2015) 880–886.
760		https://doi.org/10.1126/SCIENCE.AAA6806/SUPPL_FILE/AAA6806-
761		MARTINCORENA-SM.PDF.
762	[49]	K. Yoshida, K.H.C. Gowers, H. Lee-Six, D.P. Chandrasekharan, T. Coorens, E.F.
763		Maughan, K. Beal, A. Menzies, F.R. Millar, E. Anderson, S.E. Clarke, A.
764		Pennycuick, R.M. Thakrar, C.R. Butler, N. Kakiuchi, T. Hirano, R.E. Hynds, M.R.
765		Stratton, I. Martincorena, S.M. Janes, P.J. Campbell, Tobacco smoking and
766		somatic mutations in human bronchial epithelium, Nat. 2020 5787794 578
767		(2020) 266–272. https://doi.org/10.1038/s41586-020-1961-1.
768	[50]	T.G. Paulson, P.C. Galipeau, K.M. Oman, C.A. Sanchez, M.K. Kuhner, L.P. Smith,
769		K. Hadi, M. Shah, K. Arora, J. Shelton, M. Johnson, A. Corvelo, C.C. Maley, X.
770		Yao, R. Sanghvi, E. Venturini, A.K. Emde, B. Hubert, M. Imielinski, N. Robine,
771		B.J. Reid, X. Li, Somatic whole genome dynamics of precancer in Barrett's
772		esophagus reveals features associated with disease progression, Nat.
773		Commun. 13 (2022). https://doi.org/10.1038/s41467-022-29767-7.
774	[51]	I. Martincorena, J.C. Fowler, A. Wabik, A.R.J. Lawson, F. Abascal, M.W.J. Hall,
775		A. Cagan, K. Murai, K. Mahbubani, M.R. Stratton, R.C. Fitzgerald, P.A.
776		Handford, P.J. Campbell, K. Saeb-Parsy, P.H. Jones, Somatic mutant clones
777		colonize the human esophagus with age, Science. 362 (2018) 911–917.
778		https://doi.org/10.1126/science.aau3879.
779	[52]	A.R.J. Lawson, F. Abascal, T.H.H. Coorens, Y. Hooks, L. O'Neill, C. Latimer, K.
780		Raine, M.A. Sanders, A.Y. Warren, K.T.A. Mahbubani, B. Bareham, T.M. Butler,
781		L.M.R. Harvey, A. Cagan, A. Menzies, L. Moore, A.J. Colquhoun, W. Turner, B.
782		Thomas, V. Gnanapragasam, N. Williams, D.M. Rassl, H. Vöhringer, S.
783		Zumalave, J. Nangalia, J.M.C. Tubío, M. Gerstung, K. Saeb-Parsy, M.R. Stratton,

784	P.J. Campbell, T.J. Mitchell, I. Martincorena, E	Extensive heterogeneity in
-----	--	----------------------------

- somatic mutation and selection in the human bladder, Science. 370 (2020)
- 786 75–82. https://doi.org/10.1126/science.aba8347.
- 787 [53] C.H. Nam, J. Youk, J.Y. Kim, J. Lim, J.W. Park, S.A. Oh, H.J. Lee, J.W. Park, H.
- 788 Won, Y. Lee, S.Y. Jeong, D.S. Lee, J.W. Oh, J. Han, J. Lee, H.W. Kwon, M.J. Kim,
- 789 Y.S. Ju, Widespread somatic L1 retrotransposition in normal colorectal
- 790 epithelium, Nature 617 (2023) 540–547. https://doi.org/10.1038/s41586-

791 023-06046-z.

- 792 [54] M. Shademan, K. Zare, M. Zahedi, H. Mosannen Mozaffari, H. Bagheri
- 793 Hosseini, K. Ghaffarzadegan, L. Goshayeshi, H. Dehghani, Promoter
- methylation, transcription, and retrotransposition of LINE-1 in colorectal
- adenomas and adenocarcinomas, Cancer Cell Int. 20 (2020) 1–16.
- 796 https://doi.org/10.1186/S12935-020-01511-5.
- 797

### 799 **FIGURE LEGENDS**

800 Figure 1. RetroTest design and benchmarking. A. RetroTest design. B. 801 Scatterplot and correlation between L1 activation and orphan transductions (TD2) 802 in the International Consortium of PanCancer (PCAWG) data. The number of L1 3' 803 transductions measured L1 activation. C. Performance of RetroTest for different 804 sequencing coverages using an artificially generated GRC37/hg19 genome with a 805 total of 2,480 randomly distributed L1 transductions at 50% VAF. D. Performance 806 of RetroTest with respect to the VAF of L1 integrations, using the artificially 807 generated GRC37/hg19 genome with a total of 2,480 randomly distributed L1 808 transductions at different VAFs. E. Performance of TraFiC with respect of the VAF 809 of L1 integrations, using the artificially generated GRC37/hg19 genome with a 810 total of 2,480 randomly distributed L1 transductions at different VAFs. F. Venn 811 diagram of the number of L1 insertions detected by RetroTest and TraFiC in the 812 artificial genome with a VAF of 50% for L1 insertions.

813

Figure 2. L1 activation measured by RetroTest in the HNSCC cohort (n=96). A. 814 815 Quantification of L1 activation in HNSCC tumors as the number of orphan 816 transduction detected by RetroTest. B. Boxplot of L1 activation with respect to 817 early (T1-T2) and advanced (T3-T4) TNM stages. Differential activation p-value 818 was derived by the Wilcoxon test. To correct coverage-related bias, L1 activation 819 was calculated as the number of TD2 divided by its median coverage. **C.** Boxplot of L1 activation with respect to smoking status. Differential activation p-value was 820 derived by the Wilcoxon test. To correct coverage-related bias, L1 activation was 821 822 calculated as the number of TD2 divided by its median coverage. D. Kaplan-Meier 823 curves for overall survival with respect to L1 activation rate at T1 stage. Patients

were grouped into high (above the median) and low (below the median) L1 activation rate. Log-rank test was used to calculate the p-value. To correct coverage-related bias, L1 activation was calculated as the number of TD2 divided by its median coverage. **E.** Oncoplot showing the genes affected by L1 insertions and their original source elements. A total of 27 patients presented genes affected by L1 insertions from 46 different source elements.

830

831 Figure 3. Characterization of the mutational profile of HNSCC patients by 832 WGS (n=19). A. Oncoplot showing the genes harboring somatic mutations in 833 HNSCC patients. The type of mutation in each gene and the L1 activation (number 834 of L1 insertions in each patient) is shown. **B.** Boxplot of L1 activation with respect 835 to TP53 mutation or wild-type status. To correct coverage-related bias, L1 activation was calculated as the number of TD2 divided by its median coverage. 836 837 Differential activation p-value was derived by the Wilcoxon test. C. Barplot of the 838 Pathway enrichment analysis based on the 918 genes somatically mutated genes. 839 Enrichment p-values were calculated with the Fisher exact test. **D**. Barplot of the 840 transcription factor binding enrichment analysis based on the 918 genes 841 somatically mutated genes. Enrichment p-values were calculated with the Fisher 842 exact test.

843

Figure 4. Evaluation of L1 activation in normal adjacent tissue. A. Schematic
representation of the evaluation of the field cancerization process. B. Number of L1
active elements in normal adjacent tissue of HNSCC patients (n=9), compared to L1
activation in paired tumor tissue and PBMCs as germline control from the same
patients.

# 849 Table 1. Baseline characteristics of the HNSCC patients and

N = 96	
Mean age (range)	67.4 (38 - 90)
Sex	
Female	20
Male	71
NA	5
TNM stage	
T1	16
Τ2	19
Т3	18
T4	34
NA	9
Exitus	
No	50
Yes	38
NA	8
Alcohol	
Drinker	61
Non-drinker	24
NA	11
Smoking habits	
Smoker	64

# 850 clinicopathological results in the series.

	Non-smoker	22	
	NA	10	
851			
852			
853			
854			
855			

# 856 **Table 2. Number of HNSCC patients showing L1 activation along TNM stages.**

-	TNM stage			
	T1	T2	Т3	T4
L1 active	10	12	17	25
L1 inactive	6	7	1	9

# 858 ADDITIONAL FILES

859	Additional file 1 (pdf): Supplementary Methods: RetroTest library and target
860	sequencing; RetroTest method in detail; RetroTest benchmarking; Whole Genome
861	Sequencing and determination of mutation profile; Gene pathway databases uses
862	for enrichment analysis
863	Additional file 2 (xls): Table S1: RetroTest benchmarking. Table S2: HNSCC
864	somatic variants. Table S3: Gene pathways affected by HNSCC somatic variants.
865	Table S4: Transcription factors binding to genes affected by HNSCC somatic
866	variants. Table S5: HNSCC NAT somatic variants
867	Additional file 3 (pdf). Figure S1. Kaplan-Meier curves for overall survival in
868	HNSCC cohort with respect to (A) L1 activation status (active vs inactive) and (B)
869	L1 activation rate (with respect to the median, being high above vs low as below
870	the median). Log-rank test was used to calculate the p-value.
871	
872	
873	
874	
875	
876	
877	
878	
879	
880	
881	
882	

## 883 FIGURES

## **Figure 1.**



# 899 Figure 2.



- 911
- 912

#### Figure 3.



# 925 Figure 4. A A A Cumor tissue Normal adjacent tissue (NAT) Blood Cumor exclusive Tumor-normal shared Tumor exclusive NAT exclusive NAT exclusive

В

Patient	NAT exclusive	Tumor exclusive	Tumor-normal shared	Germline	Total
HNSCC_01	0	20	0	1	21
HNSCC_02	1	95	1	0	97
HNSCC_03	1	24	0	0	25
HNSCC_04	0	100	0	0	100
HNSCC_05	0	4	0	0	4
HNSCC_06	2	1	0	0	3
HNSCC_07	0	23	0	1	24
HNSCC_08	0	3	0	2	5
HNSCC_09	0	2	0	1	3

- 926
- 927
- 928
- 929
- 930
- 931
- 932
- 933
- \_ \_ .
- 934
- 935